Humacyte, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 25.11 million compared to USD 3.72 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.04 a year ago.

For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.